Susan Ruel

New York

Health Editor at MDedge Hematology and Oncology

Health Editor at Medscape

Featured in: Favicon

mdedge.com Favicon

reason.com Favicon

classical-scene.com Favicon

medscape.com Favicon

univadis.es Favicon

soundcloud.com Favicon

minoritynurse.com Favicon

news-decoder.com

Articles

Un dúo de fármacos mejora los resultados en el mieloma

2 months ago | univadis.es | Susan Ruel

Editado por la Dra. Susan RuelCONCLUSIÓN PRÁCTICAAgregar daratumumab al tratamiento de mantenimiento con lenalidomida después del trasplante en los pacientes con mieloma múltiple triplica la tasa de conversión de enfermedad residual mínima a negativa al 50,5 % frente al 18,8 % con lenalidomida sola. Con el tratamiento combinado se reduce el riesgo de progresión en un 47 % y se logran tasas estimadas de supervivencia libre de progresión a 30 meses del 82,7 % frente al 66,4 % con lenalidomida sola.
Myeloma: Can Lymphopenia Help Predict Patient Outcomes?

Jan 23, 2025 | mdedge.com | Susan Ruel

TOPLINE:The analysis of 11,427 US Deparment of Veterans Affairs (VA) hospital patients with multiple myeloma (MM) reveals that lymphopenia affects 53% of patients at diagnosis. The median overall survival was 2.7 years in patients with severely low absolute lymphocyte count vs 4.2 years in those with normal counts.
Myeloma: Can Failed Drugs Work Again?

Jan 16, 2025 | mdedge.com | Susan Ruel

TOPLINE:In a retrospective study of 315 patients with relapsed/refractory multiple myeloma, retreatment with previously refractory drugs achieved an overall response rate of 56.2% and median progression-free survival of 11 months. Longer initial therapy duration and greater time gap between treatments were associated with superior outcomes.
To Combat Leukemia, Researchers Harness CD37

Jan 16, 2025 | mdedge.com | Susan Ruel

TOPLINE:CD37, a surface protein present on most acute myeloid leukemia (AML) blasts, demonstrates unique internalization properties that enable targeted drug delivery with minimal impact on normal blood cells. Anti-CD37 antibody-drug conjugate (ADC) shows specific cytotoxicity to AML blasts while preserving normal hematopoietic stem cells.
Can Glucarpidase Help Reverse Methotrexate Kidney Damage?

Jan 8, 2025 | mdedge.com | Susan Ruel

TOPLINE:Glucarpidase treatment in patients with methotrexate-associated acute kidney injury is linked to 2.7 times higher odds of kidney recovery and faster recovery time. The enzyme also reduces the risk for grade ≥ 2 neutropenia and transaminitis by half vs no glucarpidase treatment. METHODOLOGY:Researchers conducted a multicenter cohort study involving 708 adults with methotrexate-associated acute kidney injury from 28 cancer centers across the United States.
SCD: Can Atrial Arrhythmias Predict Strokes?

Nov 13, 2024 | mdedge.com | Susan Ruel

TOPLINE:Atrial arrhythmias were found in 26% of patients with sickle cell disease (SCD), with a significant association with stroke history. Early detection and treatment of atrial arrhythmias may help prevent strokes in this population. METHODOLOGY:A total of 130 adult patients with SCD were included in the DREPACOEUR prospective registry from November 2018 to November 2022.
SCD: Can Atrial Arrhythmias Predict Strokes?

Nov 12, 2024 | medscape.com | Susan Ruel

TOPLINE: Atrial arrhythmias were found in 26% of patients with sickle cell disease (SCD), with a significant association with stroke history. Early detection and treatment of atrial arrhythmias may help prevent strokes in this population. METHODOLOGY:A total of 130 adult patients with SCD were included in the DREPACOEUR prospective registry from November 2018 to November 2022.
Venetoclax-Obinutuzumab: CLL’s New Power Duo?

Nov 8, 2024 | mdedge.com | Susan Ruel

TOPLINE:Venetoclax-obinutuzumab combination therapy for untreated chronic lymphocytic leukemia (CLL) shows a 6-year progression-free survival (PFS) rate of 53%. The time-to-next-treatment (TTNT) rate is 65%, with improved quality of life reported by patients. METHODOLOGY:A total of 432 patients with previously untreated CLL and coexisting conditions were enrolled in the study.
Hemofilia B: una genoterapia prometedora

Sep 25, 2024 | univadis.es | Susan Ruel

CONCLUSIÓN PRÁCTICALa genoterapia con fidanacogene elaparvovec redujo la tasa anualizada de hemorragias en un 71 % en los pacientes con hemofilia B. Los niveles de actividad del factor IX se mantuvieron en un 26,9 % a los 15 meses del tratamiento. DISEÑO DEL ESTUDIOSe realizó un estudio abierto de fase 3 en el que participaron 45 hombres de 18 a 65 años con hemofilia B y un nivel de factor IX ≤2 %.
What it took to cover an unpopular war

Jul 17, 2024 | news-decoder.com | Susan Ruel

In 1962 reporters arriving in Vietnam found an increasing U.S. military presence that wasn’t supposed to exist. Reporting what was happening took courage. Associated Press correspondent Peter Arnett, left, marches in column with Vietnamese troops as he covers the war in Vietnam, 11 November 1965.